Department of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.
Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan.
Dig Dis Sci. 2019 Oct;64(10):2982-2991. doi: 10.1007/s10620-019-05624-4. Epub 2019 Apr 22.
Although endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) has been widely used for the diagnosis of pancreatic tumors, the ability to obtain adequate pancreatic tumor tissue needs to be improved.
This study was performed to compare a newly designed 21-gauge needle (EUS Sonopsy CY; Hakko Medical, Nagano, Japan) and a standard 22-gauge needle for tissue sampling of solid pancreatic masses.
Consecutive patients with solid pancreatic masses who underwent EUS-FNA with either the EUS Sonopsy CY or the 22-gauge needle from June 2014 to December 2016 were enrolled. The primary outcome was comparison of the diagnostic yield of the FNA samples. The secondary outcomes were comparison of technical success, diagnostic ability for malignancy, and complications.
A total of 93 patients (40.9% female; mean age, 70.1 years) underwent EUS-FNA with the EUS Sonopsy CY (n = 47) or the standard 22-gauge needle (n = 46). The technical success rate was 100% in both groups, and the overall diagnostic accuracy for malignancy was similar between the groups (100% in the EUS Sonopsy CY group vs. 95.7% in the 22-gauge needle group, P = 0.242). Nevertheless, the EUS Sonopsy CY resulted in significantly higher scores for cellularity (P = 0.006) and lower scores for blood contamination (P < 0.001). The procedure-related complication rate was comparable between the groups (P = 0.148).
The EUS Sonopsy CY provided higher-quality specimens for histological evaluation in terms of both sample cellularity and blood contamination for the diagnosis of solid pancreatic masses.
The study was registered in a clinical trial registry, No. UMIN000032598.
尽管内镜超声引导下细针抽吸术(EUS-FNA)已广泛用于胰腺肿瘤的诊断,但仍需要提高获取足够胰腺肿瘤组织的能力。
本研究旨在比较一种新设计的 21 号针(EUS Sonopsy CY;Hakko Medical,长野,日本)和标准的 22 号针在胰腺实性肿块的组织取样方面的性能。
连续纳入 2014 年 6 月至 2016 年 12 月期间因胰腺实性肿块接受 EUS-FNA 的患者,分别采用 EUS Sonopsy CY 或标准 22 号针进行穿刺。主要结局是比较 FNA 样本的诊断率。次要结局是比较技术成功率、恶性肿瘤诊断能力和并发症。
共 93 例患者(40.9%为女性;平均年龄 70.1 岁)接受了 EUS-FNA,其中 47 例采用 EUS Sonopsy CY,46 例采用标准 22 号针。两组的技术成功率均为 100%,且两组的恶性肿瘤总体诊断准确性相似(EUS Sonopsy CY 组为 100%,22 号针组为 95.7%,P=0.242)。然而,EUS Sonopsy CY 组的细胞含量评分显著更高(P=0.006),血液污染评分显著更低(P<0.001)。两组的操作相关并发症发生率相当(P=0.148)。
EUS Sonopsy CY 可提供更高质量的组织学评估标本,在细胞含量和血液污染方面均优于胰腺实性肿块的诊断。
本研究在临床试验注册处注册,注册号 UMIN000032598。